brain-derived

Brain-derived acidic fibroblast growth factor (brain-derived aFGF) (1-11) is a peptide fragment of brain-derived aFGF. Brain-derived aFGF is an angiogenic vascular endothelial cell mitogen produced in bovine brain that has sequence homology to interleukin-1. aFGF (1-11) corresponds to amino acid residues 1-11 of the full length peptide.

Brain-derived acidic fibroblast growth factor (102-111) is a peptide fragment of brain-derived acidic fibroblast growth factor (aFGF). aFGF is an angiogenic vascular endothelial cell mitogen produced in bovine brain that has sequence homology to interleukin-1. It also shares sequence homology with the known neuropeptides neuromedin C , bombesin , neuromedin K , substance K , substance P , physalaemin, and eledoisin. aFGF (102-111) corresponds to amino acid residues 102-111 of the fulllength peptide.

Brain-derived basic fibroblast growth factor (1-24) (brain-derived bFGF) is a peptide fragment of brain-derived bFGF. bFGF is a peptide produced in bovine brain that is protective in a rat model of pressure-induced retinal ischemia. bFGF (1-24) corresponds to amino acid residues 1-24 of the full length peptide.

Moclobemide (Ro111163) is a reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.

Brain Derived Basic Fibroblast Growth Factor (1-24) (FGF basic 1-24), a synthetic peptide with anti-bacterial and anti-HBV properties, is utilized in infectious and immune disease research [1].

Brain Derived Acidic Fibroblast Growth Factor (1-11) is a polypeptide molecule with the sequence PALPEDGGSGAFPPGHFKDPKRLY.

Brain Derived Acidic Fibroblast Growth Factor (102-111) is a polypeptide molecule with the sequence HAEKHWFVGL.

Sonlicromanol hydrochloride (KH176 hydrochloride) is a ROS-redox modulator that crosses the blood-brain barrier, has potential anticancer activity, improves m.3243A>G heterogeneity in iPSC-derived neurons associated with It has potential anticancer activity, ameliorates neuronal network dysfunction and transcriptomic changes associated with m.3243A>G heterogeneity in iPSC-derived neurons, and can be used for the treatment of mitochondrial diseases.

4-Methylcatechol (3,4-Dihydroxytoluene) is a metabolite of homoprotocatechuic acid. It is both a substrate and a suicide inhibitor of Catechol 2,3-dioxygenase. 4-Methylcatechol (3,4-Dihydroxytoluene) is known to induce the production of brain-derived neurotrophic factor (BDNF). Recent studies have suggested that a lack of brain-derived neurotrophic factor (BDNF) in the limbic system may cause neuropathic pain.

Hemopressin (rat) acetate is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin is orally active, selective and inverse agonist of CB2 cannabinoid receptors. Hemopressin exerts antinocicep

Pramiracetam (CI-879), derived from piracetam, is a more effective nootropic drug . According to reports, Pramiracetam improved cognitive defects related with traumatic brain wounds. Pramiracetam was also potent in the therapy of cognitive disorders of traumatic origins and cerebrovascular.

Tandutinib (CT53518) (MLN518, CT53518), an effective FLT3 antagonist (IC50: 0.22 μM), can also inhibit c-Kit and PDGFR, 15-20 fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR, EGFR, and KDR.

Tau-0N4R-IN-1 (Compound 6T) is a brain-penetrant inhibitor of tau0N4R oligomerization. It effectively inhibits the fibrillization of tau 0N4R, 2N3R, and 2N4R, showcasing potent anti-seeding effects against tau in vitro, and can dose-dependently reduce α-syn oligomerization while preventing the formation of α-syn inclusions. Tau-0N4R-IN-1 demonstrates stability in mouse microsomes and reduces Aβ plaques derived from the brain tissue of AD patients. Moreover, it exhibits favorable pharmacokinetic properties in mice.

BNN-20 is a synthetic micro-neurotrophic factor that mimics Brain-Derived Neurotrophic Factor (BDNF) and exhibits region-specific neuroprotective and neurogenesis-promoting effects. It is applicable in research related to Parkinson's disease.

RNA binder 1 (Compound 4b) is an RNA-binding agent capable of crossing the blood-brain barrier. It selectively binds to the G-quadruplex structure of the G4C2 repeat sequence RNA of the C9orf72 gene. This compound significantly reduces levels of the toxic polypeptides poly(GA) and poly(GP) in cells derived from amyotrophic lateral sclerosis (ALS) patients, while it has no significant impact on the antisense polypeptide poly(PR), demonstrating selectivity for sense RNA. RNA binder 1 is useful for studying ALS and frontotemporal dementia (FTD).

EGFR-IN-91 (compound 9) is an orally active EGFR inhibitor capable of crossing the blood-brain barrier. It effectively inhibits EGFRL858R/C797S and EGFRexon 19del/C797S, leading to tumor regression in patient-derived xenograft (PDX) mouse models. EGFR-IN-91 shows potential for inhibiting locally advanced and metastatic non-small cell lung cancer (NSCLC) driven by EGFR mutations.

(2R,4R)-APDC hydrate ((2R,4R)-4-Aminopyrrolidine-2,4-dicarboxylic acid hydrate) is an agonist for group II metabotropic glutamate receptors (mGluR). It influences cell proliferation by inhibiting glutamate release, enhancing motor responses generated by D1 receptor activation, or reducing brain-derived neurotrophic factor (BDNF) levels. This compound is applicable in research on epilepsy and other neurological disorders.

PX5-9 is a prodrug that can enhance the expression of brain-derived neurotrophic factor (BDNF). It shows potential for research into BDNF-related diseases, such as neurodegenerative disorders.

MXC-017 is an apoptosis inducer capable of crossing the blood-brain barrier, specifically targeting glioma stem cells (GSCs). It effectively prevents the formation of radiation-induced GSCs while promoting G0/G1 cell cycle arrest and apoptosis. With minimal off-target effects, MXC-017 exhibits no significant cytotoxicity even at concentrations up to 10 µM. Additionally, it significantly extends the median survival in patient-derived orthotopic xenograft (PDOX) glioblastoma (GBM) mouse models when used in conjunction with radiation therapy.

Neuroprotective agent 14 is a 1H-benzimidazole [d] compound that can penetrate the blood-brain barrier and is known for its neuroprotective properties. It activates autophagy (autophagy) and reduces the accumulation of SCMAS in iPSC-derived neural progenitor cells. This agent is useful for studying neurological disorders such as neuronal ceroid lipofuscinoses (NCLs).

Neuroprotective agent 13 is a 1H-benzimidazole [d] class compound with neuroprotective properties that can penetrate the blood-brain barrier. It activates autophagy (autophagy) and mitigates the accumulation of SCMAS in induced pluripotent stem cell (iPSC) derived neural progenitor cells. Neuroprotective agent 13 is applicable in the study of neurological disorders such as neuronal ceroid lipofuscinoses (NCLs).

KMCA-0011 is an orally active antagonist of the ɑ2C adrenoceptor (Ki= 56.7 nM). It alleviates depressive behavior by enhancing brain-derived neurotrophic factor (BDNF) and synaptic plasticity. KMCA-0011 demonstrates excellent metabolic stability, maintaining 99.8% plasma stability after 120 minutes. It is a useful compound for researching depression.

α-Casozepine, a bioactive peptide derived from milk α-S1 casein, exhibits affinity for γ-aminobutyric acid (GABA) receptors in the brain and demonstrates anti-anxiety effects.

Cytochrome P450 metabolism of polyunsaturated fatty acids produces numerous bioactive epoxide regioisomers. (±)10(11)-EpDPA is a docosahexaenoic acid epoxygenase metabolite, derived via epoxidation of the 10,11-double bond of DHA. It has been detected in rat brain and spinal cord, as well as human serum, and acts as a substrate for soluble epoxide hydrolase with a Km value of 5.1 μM. (±)10(11)-EpDPA and other epoxy metabolites of DHA are reported to demonstrate antihyperalgesic activity in inflammatory and neuropathic pain models and to potently inhibit angiogenesis and tumor growth in in vitro assays.